Tailoring the management of hypertension to comorbidities Article

Full Text via DOI: 10.1097/HCO.0000000000000860 Web of Science: 000661895200006
International Collaboration

Cited authors

  • Mendoza MF, Kachur SM, Lavie CJ


  • Purpose of review In this article, we review the most current evidence for initiation and maintenance of various antihypertension (HTN) drug classes, including other misconceptions with respect to common comorbidities in patients with HTN. Recent findings Although the currently available anti-HTN agents have broad applicability in treating HTN, additional agents, such as angiotensin receptor-neprilysin inhibitors and novel nonsteroidal mineralocorticoid antagonists, have recently gained clinical significance. In addition, there have been some anecdotal concerns regarding the adverse effects, indications, and risks of COVID-19 infection/mortality when using certain anti-HTN agents. Current guidelines currently address the treatment of primary HTN. However, isolated HTN is uncommon and often involves comorbid diseases that require specific regimentation. Several experimental medications are currently in late-stage trials showing potential superiority over current drugs that are available in the market.

Publication date

  • 2021

Published in

International Standard Serial Number (ISSN)

  • 0268-4705

Number of pages

  • 8

Start page

  • 405

End page

  • 412


  • 36


  • 4